Cellect Announces Positive Results from Cell2in Collaboration Showing Significant Improvement in Expansion Rate and Function of Stem Cells
March 11, 2019 at 04:30 pm IST
Cellect Biotechnology Ltd. announced positive preliminary results from its collaboration with Cell2in, a privately-held South Korean company focused on improving the quality of stem cells. Results of this third-party study further validate that Cellect's Apograft technology significantly improves both proliferation and functional capabilities of hematopoietic (HSC) and mesenchymal (MSC) stem cells originating from bone marrow, peripheral blood, umbilical cord, and adipose tissue. Higher degree of stemness (both in Cell2in and standard assays) maintained through repeated expansions of bone marrow and umbilical cord derived mesenchymal stem cells Improved expansion of adipose derived mesenchymal stem cells in early and late passages Significantly increased stemness of hematopoietic stem cells within two hours of the ApoGraft™ process.